Posts tagged as: financing back to homepage

Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug(0)

The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess.  After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND.  This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More

Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0)

Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug.  The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.